Covid-19 manufacturing roundup: After Emergent disaster, AstraZeneca in talks to move to Catalent plant — report; Sinopharm says it has capacity to produce 5B vaccines
After months of production of its vaccine plagued by a mixup at a Baltimore Emergent plant that has been taken over by the FDA, AstraZeneca …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
